trastuzumab   Click here for help

GtoPdb Ligand ID: 5082

Synonyms: D5v8 | Herceptin® | R-597
Approved drug
trastuzumab is an approved drug (FDA (1998), EMA (2000))
Compound class: Antibody
Comment: Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

NameTrade nameCompanyClinical PhaseIndications
trastuzumab-dkst; MYL-1401OHertraz; Canmab; OgivriMylan and Biocon Approved in India, FDA 2017, EMA 2018 (Ogivri)Breast cancer
trastuzumab-pkrb; CT-P6Herzuma; CredimaCelltrionApproved in S Korea, EMA & FDA 2018Breast cancer
trastuzumab-dttb; SB3OntruzantSamsung BioepisApproved (EMA 2017, FDA 2019)All approved indications of the reference product
trastuzumab-beta; trastuzumab-anns; ABP-980 [3]KanjintiAmgen/AllerganApproved (EMA 2018, FDA 2019)All approved indications of the reference product
trastuzumab-qyyp; PF-05280014TrazimeraPfizerApproved (FDA 2019; see REFLECTIONS B327-02 trial NCT01989676)All approved indications of the reference product
HLX02ZercepacShanghai Henlius Biotech; Accord HealthcareApproved (EMA 2020)Approved to treat HER2 positive metastatic breast cancer
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trastuzumab

Bioactivity Comments
The use of anti-HER2 monoclonals is covered by patent WO1989006692, in which the clone that produced trastuzumab is 4D5 [1]. Efficacy of the resultant monoclonals was assessed in vitro (for example ELISA for antigen binding and in vitro cellular assays for anti-tumour activity) but no affinity value for the interaction between the antibody and its antigen are provided in the patent.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
erb-b2 receptor tyrosine kinase 2 Primary target of this compound Hs Antibody Inhibition - - -
Ligand mentioned in the following text fields